|
|
Volumn 14, Issue 1, 2014, Pages 5-6
|
|
Anticoagulant antidotes start yielding Phase III promise
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANDEXANET ALFA;
ANTICOAGULANT AGENT;
ANTIDOTE;
APIXABAN;
BLOOD CLOTTING FACTOR 10A;
DABIGATRAN;
DRUG ANTIBODY;
EDOXABAN;
IDARUCIZUMAB;
PER 977;
RIVAROXABAN;
UNCLASSIFIED DRUG;
WARFARIN;
MONOCLONAL ANTIBODY;
ANTICOAGULANT THERAPY;
BLEEDING;
DRUG EFFICACY;
HUMAN;
INFUSION RELATED REACTION;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SHORT SURVEY;
SINGLE DRUG DOSE;
THROMBOSIS;
UNSPECIFIED SIDE EFFECT;
ORAL DRUG ADMINISTRATION;
TRENDS;
ADMINISTRATION, ORAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTICOAGULANTS;
ANTIDOTES;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
|
|
EID: 84925283577
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4527 Document Type: Short Survey |
|
Times cited : (6)
|
|
References (0)
|
